Your browser doesn't support javascript.
loading
The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas.
Li, Kai; Ma, Lei; Sun, Ye; Li, Xiang; Ren, Hong; Tang, Shou-Ching; Sun, Xin.
Afiliação
  • Li K; Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, Shaanxi, China.
  • Ma L; Department of Thoracic Surgery and Oncology, Cancer Centre, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, Shaanxi, China.
  • Sun Y; Department of Anesthesiology and Perioperative Medicine, Operating Centre, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
  • Li X; Department of Anesthesiology and Operation, Operating Centre, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
  • Ren H; Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, Shaanxi, China.
  • Tang SC; Department of Thoracic Surgery and Oncology, Cancer Centre, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, Shaanxi, China.
  • Sun X; Department of Pathology, Anatomy and Cell Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Sci Rep ; 11(1): 18587, 2021 09 20.
Article em En | MEDLINE | ID: mdl-34545132
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Ligante OX40 / Antineoplásicos Imunológicos / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Ligante OX40 / Antineoplásicos Imunológicos / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China